Catheter Precision reported third‑quarter 2025 revenue of $226,000, a 135% increase from $96,000 in the same period a year earlier, and first‑nine‑month revenue of $581,000, up 114% from $271,000 in 2024. The company’s GAAP net loss narrowed to $2.251 million from $4.120 million in Q3 2024 and to $11.405 million for the nine‑month period from $11.015 million a year earlier, a 45% reduction in loss.
The growth was driven by expanding international sales of the LockeT suture‑retention device and the VIVO non‑invasive 3D cardiac mapping system. LockeT’s CE Mark approval in May 2025 and subsequent UK approval in August 2025 opened key European markets, while VIVO secured its first purchase order from France in October and additional orders from Sweden and Croatia. Two VIVO clinical studies completed in 2025 provided strong evidence of efficacy, bolstering demand.
Despite the revenue gains, the company remains in a net‑loss position and disclosed a “going‑concern” warning in its filing. Management highlighted the need for additional capital and noted that Catheter Precision has been raising funds through private placements and an at‑the‑market program to support ongoing operations and product development.
CEO David Jenkins said the quarter “represents a pivotal period of growth” and that the company is “poised to expand both product lines across the U.S. and international markets.” He added that the completion of two VIVO clinical studies in 2025 “provides powerful clinical evidence” and that the system “has the potential to transform ventricular arrhythmia treatment.”
The results underscore the company’s strategy of leveraging regulatory approvals and clinical data to accelerate market penetration. However, the continued net losses and the going‑concern warning signal that Catheter Precision must sustain capital inflows and manage costs to achieve profitability. The company’s focus on international expansion and clinical validation remains a key driver of its growth trajectory, but investors will watch how the firm balances investment with financial stability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.